Talk:Huperzine A: Difference between revisions

Content deleted Content added

Inline

Revision as of 18:50, 24 October 2016

Chemicals Start‑class Mid‑importance

	This article is within the scope of WikiProject Chemicals, a daughter project of WikiProject Chemistry, which aims to improve Wikipedia's coverage of chemicals. To participate, help improve this article or visit the project page for details on the project.ChemicalsWikipedia:WikiProject ChemicalsTemplate:WikiProject Chemicalschemicals
Start	This article has been rated as Start-class on Wikipedia's content assessment scale.
Mid	This article has been rated as Mid-importance on the project's importance scale.

IUPAC Name lacks stereochemistry

IUPAC Name lacks stereochemistry. Suggested name awaiting validation (1R,9S,13E)-1-amino-13-ethylidene-11-methyl-6-azatricyclo[7.3.1.0^(2,7)]trideca-2(7),3,10-trien-5-one--ChemSpiderMan (talk) 17:24, 14 January 2008 (UTC)[reply]

Now fixed. Walkerma (talk) 05:58, 20 January 2008 (UTC)[reply]

The assigned stereochemistry is wrong it is a (1R, 9R, 13E)-.... check any source (chemspider, scifinder and so on) — Preceding unsigned comment added by 130.208.176.1 (talk) 14:15, 26 November 2015 (UTC)[reply]

possible 10 IQ point raise, confusing reference

this pubmed reference says of schizophrenics given huperzine A "RESULTS:

Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p < 0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups. " It is possible that WMD (weighted mean difference) suggests 10.59, 3.97, IQ piint increase, with a 12.79 (WMD) reduction of errors. However I may be wildly misinterpreting tha data.

More RCTs are needed

Recent Cochrane reliable reviews have failed to show the effectiveness of huperzine A on vascular dementia and Alzheimer's disease (AD), however this seems to occur due to the lack of reliable contemporary RCTs (randomized controlled studies). To my mind, and after extensive research on the Pubmed studies, huperzine A seems promising on cognitive decline (especially on age - related), however more studies on humans are needed. The proper dose is also a question, as well as using on studies pharmaceutical forms with high bioavailability. Comparing to the rest AchE inhibotors, huperzine A seems more safer with less adverse effects. Moreover, further mechanisms, than inhibition of AchE, are implicated, such as antioxidant properties.688dim (talk) 20:05, 3 July 2013 (UTC)[reply]

@@ Line 10: / Line 10: @@
 The assigned stereochemistry is wrong it is a (1R, 9R, 13E)-....
 check any source (chemspider, scifinder and so on)  <small class="autosigned">—&nbsp;Preceding [[Wikipedia:Signatures|unsigned]] comment added by [[Special:Contributions/130.208.176.1|130.208.176.1]] ([[User talk:130.208.176.1|talk]]) 14:15, 26 November 2015 (UTC)</small><!-- Template:Unsigned IP --> <!--Autosigned by SineBot-->
+== possible 10 IQ point raise, confusing reference ==
+this pubmed reference says of '''schizophrenics''' given huperzine A "RESULTS:
+Twelve RCTs (n = 1117) lasting 11.7 ± 6.0 weeks met inclusion criteria. All had been conducted in China. HupA outperformed comparators on the following outcome measures: the Wechsler Memory Scale-Revised including memory quotient (weighted mean difference (WMD: 10.59; 95% confidence interval (CI): 5.65, 15.53; p < 0.0001); Wechsler Adult Intelligence Scale-Revised including verbal intelligence quotient (IQ), performance IQ, and full IQ (WMD: 3.97 to 5.66; 95%CI: 0.20, 8.58; p = 0.01 to 0.00001); Wisconsin Card Sorting Test including response administer and non-perseverative errors (WMD: -12.79 to -12.29; 95%CI: -23.70, -0.88; p = 0.03 to 0.003). In studies using the Positive and Negative Syndrome Scale (n = 7)/Brief Psychiatric Rating Scale (n = 1), the differences in total score were significant (standard mean difference: -0.77; 95%CI: -1.27, -0.27; p = 0.002). All-cause discontinuation (risk ratio: 0.67; 95%CI: 0.36, 1.24; p = 0.20) and adverse events were similar between groups.
+"  It is possible that WMD (weighted mean difference) suggests 10.59, 3.97, IQ piint increase, with a 12.79 (WMD) reduction of errors.  '''However I may be wildly misinterpreting tha data.'''
 == More RCTs are needed==